跳转至内容
Merck
CN

Angiogenesis and remodelling in human thoracic aortic aneurysms.

Cardiovascular research (2014-08-21)
Ketty Kessler, Luciano F Borges, Benoît Ho-Tin-Noé, Guillaume Jondeau, Jean-Baptiste Michel, Roger Vranckx
摘要

Human thoracic aneurysm of the ascending aorta (TAA) is a chronic disease characterized by dilatation of the aortic wall, which can progress to vessel dissection and rupture. TAA has several aetiologies, but all forms present common features, including tissue remodelling. Here, we determined and characterized the angiogenic process associated with TAA and its relation with wall remodelling. Immunostaining for blood vessels showed an increased density of microvessels originating from the adventitia in the external medial layer of TAA compared with healthy aortas. Proteomic array analysis of 55 angiogenic factors in medial and adventitial layers showed different expression profiles in both tissue compartments between aneurysmal and healthy aortas. Quantification by ELISA confirmed that all forms of TAA contained higher levels of several pro- and anti-angiogenic factors, including angiopoietin-1 and -2, fibroblast growth factor-acidic, and thrombospondin-1, than that of healthy aortas. However, all groups showed comparable levels of vascular endothelial growth factor-A. Quantitative RT-PCR demonstrated that angiopoietins were overexpressed in TAA media. Immunostaining and electron microscopy revealed that neovessels had defective endothelial junctions and poor mural cell coverage. This incomplete structure was associated with the accumulation of plasminogen and albumin in the media of TAA. We describe, for the first time, leaky neovessel formation in TAA media in association with an imbalance of angiogenic factor levels. Although the initiating mechanisms of neo-angiogenesis in TAA and the potential aetiology-related differences remain to be determined, our results suggest that neo-angiogenesis could participate in TAA wall remodelling and weakening through deposition of blood-borne zymogens.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
四氢呋喃, inhibitor-free, suitable for HPLC, ≥99.9%
Sigma-Aldrich
四氢呋喃, contains 200-400 ppm BHT as inhibitor, ACS reagent, ≥99.0%
Sigma-Aldrich
四氢呋喃, anhydrous, ≥99.9%, inhibitor-free
Sigma-Aldrich
四氢呋喃, anhydrous, contains 250 ppm BHT as inhibitor, ≥99.9%
Sigma-Aldrich
四氢呋喃, ≥99.0%, contains 200-400 ppm BHT as inhibitor, ReagentPlus®
Sigma-Aldrich
四氢呋喃, contains 250 ppm BHT as inhibitor, puriss. p.a., ACS reagent, reag. Ph. Eur., ≥99.9%
Sigma-Aldrich
四氢呋喃, ACS reagent, ≥99.0%, contains 200-400 ppm BHT as inhibitor
Sigma-Aldrich
苯甲酸苄酯, ReagentPlus®, ≥99.0%
Sigma-Aldrich
苯甲酸苄酯, ≥99%, FCC, FG
Supelco
四氢呋喃, analytical standard
Supelco
四氢呋喃, Pharmaceutical Secondary Standard; Certified Reference Material
USP
苯甲酸苄酯, United States Pharmacopeia (USP) Reference Standard
Supelco
苯甲酸苄酯, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
苯甲酸苄酯, natural, ≥99%, FG
Supelco
四氢呋喃, Selectophore, ≥99.5%
Supelco
苯甲酸苄酯, analytical standard
Sigma-Aldrich
苯甲酸苄酯, meets USP testing specifications
Sigma-Aldrich
四氢呋喃, inhibitor-free, purification grade